The role of screening and monitoring for bleomycin pulmonary toxicity.
Bleomycin-induced pulmonary toxicity can have a significant impact on patient outcomes. However, no guidelines for ideal screening and monitoring are available. This paper reviews the literature to identify the best way to monitor and reduce patient risk for bleomycin pulmonary toxicity. We have created evidence-based guidelines to help healthcare professionals identify patient risk factors and provide appropriate assessment and monitoring for patients receiving bleomycin therapy.
Department of Pharmacy, UAB Medicine, Birmingham, AL, USA bmshippee@uabmc.edu.
Brittney M
BM
Shippee
Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA.
Jill S
JS
Bates
UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA Division of Hematology/Oncology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kristy L
KL
Richards
D000367:Age Factors; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects*; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced* / Q000175:diagnosis* / Q000453:epidemiology; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin
Bleomycin; monitoring; pulmonary toxicity; risk factors